Literature DB >> 29405353

Congenital myasthenic syndromes with acetylcholinesterase deficiency, the pathophysiological mechanisms.

Claire Legay1.   

Abstract

The neuromuscular junction (NMJ) is a cholinergic synapse in vertebrates. This synapse connects motoneurons to muscles and is responsible for muscle contraction, a physiological process that is essential for survival. A key factor for the normal functioning of this synapse is the regulation of acetylcholine (ACh) levels in the synaptic cleft. This is ensured by acetylcholinesterase (AChE), which degrades ACh. A number of mutations in synaptic genes expressed in motoneurons or muscle cells have been identified and are causative for a class of neuromuscular diseases called congenital myasthenic syndromes (CMSs). One of these CMSs is due to deficiency in AChE, which is absent or diffuse in the synaptic cleft. Here, I focus on the origins of the syndrome. The role of ColQ, a collagen that anchors AChE in the synaptic cleft, is discussed in this context. Studies performed on patient biopsies, transgenic mice, and muscle cultures have provided a more comprehensive view of the connectome at the NMJ that should be useful for understanding the differences in the symptoms observed in specific CMSs due to mutated proteins in the synaptic cleft.
© 2018 New York Academy of Sciences.

Entities:  

Keywords:  ColQ; MuSK; acetylcholine receptor; acetylcholinesterase; congenital myasthenic syndromes; neuromuscular junction

Mesh:

Substances:

Year:  2018        PMID: 29405353     DOI: 10.1111/nyas.13595

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  5 in total

1.  Adrenaline Facilitates Synaptic Transmission by Synchronizing Release of Acetylcholine Quanta from Motor Nerve Endings.

Authors:  Venera Khuzakhmetova; Ellya Bukharaeva
Journal:  Cell Mol Neurobiol       Date:  2020-04-09       Impact factor: 5.046

Review 2.  Autoregulation of Acetylcholine Release and Micro-Pharmacodynamic Mechanisms at Neuromuscular Junction: Selective Acetylcholinesterase Inhibitors for Therapy of Myasthenic Syndromes.

Authors:  Konstantin A Petrov; Evgeny E Nikolsky; Patrick Masson
Journal:  Front Pharmacol       Date:  2018-07-12       Impact factor: 5.810

3.  AChR β-Subunit mRNAs Are Stabilized by HuR in a Mouse Model of Congenital Myasthenic Syndrome With Acetylcholinesterase Deficiency.

Authors:  Jennifer Karmouch; Perrine Delers; Fannie Semprez; Nouha Soyed; Julie Areias; Guy Bélanger; Aymeric Ravel-Chapuis; Alexandre Dobbertin; Bernard J Jasmin; Claire Legay
Journal:  Front Mol Neurosci       Date:  2020-12-09       Impact factor: 5.639

Review 4.  Novel copy number variation of COLQ gene in a Moroccan patient with congenital myasthenic syndrome: a case report and review of the literature.

Authors:  Youssef El Kadiri; Ilham Ratbi; Abdelaziz Sefiani; Jaber Lyahyai
Journal:  BMC Neurol       Date:  2022-08-05       Impact factor: 2.903

Review 5.  The Neuromuscular Junction and Wide Heterogeneity of Congenital Myasthenic Syndromes.

Authors:  Pedro M Rodríguez Cruz; Jacqueline Palace; David Beeson
Journal:  Int J Mol Sci       Date:  2018-06-05       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.